Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Q32 Bio (QTTB) announced that results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) will be presented at the 2025 American Academy of Dermatology Annual Meeting in Orlando.
The presentation will highlight findings from the randomized, placebo-controlled trial evaluating bempikibart, a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling in severe and very severe alopecia areata patients.
The late-breaking oral presentation will be delivered by Dr. Brett King of Dermatology Physicians of Connecticut on March 8, 2025. The company views the selection for late-breaking presentation status as recognition of bempikibart's promising clinical activity and well-tolerated safety profile.
Q32 Bio (QTTB) ha annunciato che i risultati della Parte A del suo trial clinico SIGNAL-AA di fase 2a su bempikibart in pazienti con alopecia areata (AA) saranno presentati al Congresso Annuale dell'Accademia Americana di Dermatologia del 2025 a Orlando.
La presentazione metterà in evidenza i risultati dello studio randomizzato e controllato con placebo che valuta bempikibart, un anticorpo anti-IL-7Rα completamente umano progettato per riorganizzare la funzione immunitaria adattativa bloccando il segnale di IL-7 e TSLP nei pazienti con alopecia areata severa e molto severa.
La presentazione orale dell'ultimo minuto sarà tenuta dal Dr. Brett King dei Dermatology Physicians of Connecticut l'8 marzo 2025. L'azienda considera la selezione per lo status di presentazione dell'ultimo minuto come un riconoscimento dell'attività clinica promettente di bempikibart e del suo profilo di sicurezza ben tollerato.
Q32 Bio (QTTB) anunció que los resultados de la Parte A de su ensayo clínico SIGNAL-AA de fase 2a sobre bempikibart en pacientes con alopecia areata (AA) se presentarán en la Reunión Anual de la Academia Americana de Dermatología 2025 en Orlando.
La presentación destacará los hallazgos del ensayo aleatorizado y controlado con placebo que evalúa bempikibart, un anticuerpo anti-IL-7Rα completamente humano diseñado para re-regular la función inmune adaptativa bloqueando la señalización de IL-7 y TSLP en pacientes con alopecia areata severa y muy severa.
La presentación oral de última hora será realizada por el Dr. Brett King de Dermatology Physicians of Connecticut el 8 de marzo de 2025. La empresa considera la selección para el estado de presentación de última hora como un reconocimiento de la prometedora actividad clínica de bempikibart y su perfil de seguridad bien tolerado.
Q32 Bio (QTTB)는 탈모증(Alopecia Areata, AA) 환자를 대상으로 한 bempikibart의 SIGNAL-AA 2a 임상 시험 A 부분의 결과가 2025년 올랜도에서 열리는 미국 피부과 학회 연례 회의에서 발표될 것이라고 발표했습니다.
이번 발표에서는 bempikibart를 평가하는 무작위 이중 맹검, 위약 대조 시험의 결과가 강조될 것입니다. bempikibart는 IL-7 및 TSLP 신호를 차단하여 심각하고 매우 심각한 탈모증 환자에서 적응 면역 기능을 재조정하도록 설계된 완전 인간 항체입니다.
최신 발표는 2025년 3월 8일 코네티컷 피부과 의사인 Brett King 박사에 의해 진행될 예정입니다. 회사는 최신 발표 상태의 선정이 bempikibart의 유망한 임상 활동과 잘 견딜 수 있는 안전성 프로필에 대한 인정을 의미한다고 보고 있습니다.
Q32 Bio (QTTB) a annoncé que les résultats de la Partie A de son essai clinique SIGNAL-AA de phase 2a sur bempikibart chez des patients atteints d'alopécie areata (AA) seront présentés lors de la Réunion Annuelle de l'Académie Américaine de Dermatologie en 2025 à Orlando.
La présentation mettra en avant les résultats de l'essai randomisé contrôlé par placebo évaluant bempikibart, un anticorps anti-IL-7Rα entièrement humain conçu pour réguler à nouveau la fonction immunitaire adaptative en bloquant la signalisation de l'IL-7 et de TSLP chez les patients atteints d'alopécie areata sévère et très sévère.
La présentation orale de dernière minute sera faite par le Dr Brett King des Dermatology Physicians of Connecticut le 8 mars 2025. L'entreprise considère la sélection pour le statut de présentation de dernière minute comme une reconnaissance de l'activité clinique prometteuse de bempikibart et de son profil de sécurité bien toléré.
Q32 Bio (QTTB) gab bekannt, dass die Ergebnisse aus Teil A seiner SIGNAL-AA Phase 2a klinischen Studie zu bempikibart bei Patienten mit Alopecia Areata (AA) auf dem Jahreskongress der American Academy of Dermatology 2025 in Orlando präsentiert werden.
Die Präsentation wird die Ergebnisse der randomisierten, placebo-kontrollierten Studie hervorheben, die bempikibart bewertet, einen vollständig humanen Anti-IL-7Rα-Antikörper, der entwickelt wurde, um die adaptive Immunfunktion zu regulieren, indem er die IL-7- und TSLP-Signalübertragung bei Patienten mit schwerer und sehr schwerer Alopecia Areata blockiert.
Die späte mündliche Präsentation wird am 8. März 2025 von Dr. Brett King von Dermatology Physicians of Connecticut gehalten. Das Unternehmen betrachtet die Auswahl für den Status der späten Präsentation als Anerkennung der vielversprechenden klinischen Aktivität und des gut verträglichen Sicherheitsprofils von bempikibart.
- Selected for late-breaking presentation status at major medical conference
- Promising clinical activity reported in Phase 2a trial
- Well-tolerated safety profile indicated
- None.
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) --
"We are honored that the Phase 2a SIGNAL-AA data from bempikibart was selected for an oral late-breaking presentation at this year's AAD annual meeting, which provides recognition of its promising clinical activity and well-tolerated safety profile. This acknowledgement reinforces our conviction in bempikibart's potential to transform the treatment paradigm for a disease in desperate need of better options," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "The growing enthusiasm in the field underscores our decision to focus on advancing bempikibart in AA, and we look forward to sharing our results."
Oral Presentation Details:
Title: Initial Results from the SIGNAL-AA Study: Randomized Placebo Controlled Phase 2a Trial of a Bempikibart, Novel IL-7/TSLP Bifunctional Receptor Antagonist in Patients with Severe or Very Severe Alopecia Areata
Presenter: Brett King, M.D., Ph.D., of Dermatology Physicians of
Session Title: S028 - Late-Breaking Research: Session 1
Date & Time: Saturday, March 8, 2025, from 10:36 a.m. to 10:48 a.m. ET
Location: Chapin Theater – Level II
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases.
Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases being evaluated in a Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our investors and the public using our company website www.Q32Bio.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the
Forward-looking statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support our current beliefs and expectations for bempikibart, future clinical studies, including that Part B of the SIGNAL-AA Phase 2a clinical trial, may not be completed by the first half of 2026 or at all, might be more costly than expected or might not yield anticipated results, and such other risks and uncertainties identified in the Company's periodic, current and other filings with the
Contacts:
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-announces-late-breaking-presentation-of-results-from-signal-aa-part-a-clinical-trial-of-bempikibart-in-alopecia-areata-at-the-2025-american-academy-of-dermatology-annual-meeting-302388185.html
SOURCE Q32 Bio
FAQ
What are the key findings from Q32 Bio's SIGNAL-AA Phase 2a trial of bempikibart (QTTB)?
How does bempikibart work in treating alopecia areata?
When and where will Q32 Bio (QTTB) present the SIGNAL-AA trial results?
What phase of clinical development is bempikibart currently in for alopecia areata?
